Baseline Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Clinical Trial

Rema Raman, Kedir Hussen, Michael C Donohue, Oliver Langford, Doris P Molina‐Henry, Paul S S Aisen, Reisa A Sperling, Joshua D Grill, the A4 Study Team · 2025

Read Baseline Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Clinical Trial by Rema Raman, Kedir Hussen, Michael C Donohue, Oliver Langford, Doris P Molina‐Henry, Paul S S Aisen, Reisa A Sperling, Joshua D Grill, the A4 Study Team (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712999.txt.

Description

Rema Raman and co-authors present a 2025 study of why people drop out of a major Alzheimer trial. The A4 Study tested anti-amyloid treatment in people with no symptoms yet. Dropout can drain a trial of power and skew its results, so keeping members matters as much as enrolling them.

Of 1,169 people enrolled and followed for 4.5 years, 339 left the trial, about 29 percent. Most who left said they no longer wished to continue, and side effects came second. Older age and higher baseline anxiety raised the odds of leaving. A family history of dementia and a risk gene form slightly lowered the odds. Sex, race, test scores, and brain scans did not predict dropout. The team plans to study later-life factors as well.

Catalog record

CREATORRema Raman, Kedir Hussen, Michael C Donohue, Oliver Langford, Doris P Molina‐Henry, Paul S S Aisen, Reisa A Sperling, Joshua D Grill, the A4 Study Team
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712999

Browse the full library · About the Tower of Babel